Nearly 30 million people in the United States — and probably many others whose illnesses were never diagnosed — have been infected with the coronavirus so far. Should these people still be vaccinated?
Two new studies answer that question with an emphatic yes.
In fact, the research suggests that for these people just one dose of the vaccine is enough to turbocharge their antibodies and destroy the coronavirus — and even some more infectious variants.
Israel’s largest COVID-19 testing lab says it has found evidence indicating that the Pfizer-BioNTech vaccine significantly reduces the transmissibility of the coronavirus, offering a tentative answer to one of the world’s most burning questions.
* Germany is planning to spend nearly 9 billion euros this year to buy up to 635.1 million COVID-19 vaccines as part of the European Union’s procurement scheme and national deals.
LONDON — Britain is on a pace to give the first shot of a two-dose coronavirus vaccine to its entire population by the end of June, if it can avoid supply and logistical issues that threaten to slow one of the world’s fastest rollouts.
The most vulnerable will get their first doses much sooner — likely over the next two weeks — which could drastically reduce deaths. People over 70, nursing home residents and workers, health and social workers, and those whose health problems make them extremely vulnerable are all on schedule to receive their first vaccine shots before Feb. 15. Together these groups have accounted for 88 percent of all Covid-19 deaths.
The timeline shows the promise of vaccination as a path out of the deadliest stage of the pandemic in the countries that are moving quickly. ...
Pfizer’s coronavirus vaccine is showing 92 percent effectiveness in Israel, according to the world’s first big controlled investigation on how it works outside of clinical tests.
Recent Comments